Product image of Lenalidomida Stada (Lenalidomide) supplied by GNH India

Lenalidomida Stada

Active Ingredient:
Lenalidomide
Origin:
EU

Lenalidomida Stada (Lenalidomide)

Lenalidomide, the active ingredient in Lenalidomida Stada, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in appropriate patients.

GNH India supplies Lenalidomida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratorio Stada, S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.
  • Multiple Myeloma: improves progression‑free survival and overall response rates when combined with dexamethasone or proteasome inhibitors.
  • Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and cytopenias.
  • Mantle Cell Lymphoma: enhances response when added to standard chemo‑immunotherapy regimens.

How It Works

  • Lenalidomide binds to the cereblon component of the CRL4 E3 ubiquitin ligase complex, altering its substrate specificity. This leads to degradation of transcription factors Ikaros and Aiolos, resulting in anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects through enhanced NK‑cell activity and inhibition of cytokine production.

Side Effects

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Neutropenia: reduced neutrophil count, increasing infection risk.
  • Thrombocytopenia: low platelet levels, may cause bleeding.
  • Fatigue: persistent tiredness.
  • Nausea: upset stomach and vomiting.
  • Diarrhea: loose stools.
  • Rash: mild skin irritation.

Serious or Rare Side Effects

  • Venous thromboembolism: blood clots in deep veins or lungs.
  • Severe neutropenia: profound immune suppression.
  • Secondary primary malignancies: emergence of new cancers.
  • Tumor lysis syndrome: rapid tumor cell breakdown.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatic failure: liver dysfunction with jaundice.

Precautions & Warnings

  • Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.
  • Pregnancy: contraindicated; ensure effective contraception.
  • Renal impairment: assess renal function and adjust dose if needed.
  • Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients.
  • Hematologic monitoring: perform regular CBC to detect cytopenias.
  • Drug interactions: review concomitant medications for potential CYP3A4 effects.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Avoid Interactions

Lenalidomide can interact with several agents, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding.
  • Live vaccines: heightened infection risk due to immunosuppression.
  • Teratogenic agents: combined exposure contraindicated in pregnancy.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors (e.g., ketoconazole): may increase drug levels.
  • NSAIDs: potential additive renal toxicity.
  • Antihistamines: may enhance sedation or dizziness.

Frequently Asked Questions

Lenalidomida Stada contains lenalidomide and is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with deletion 5q, and mantle cell lymphoma, typically as part of combination therapy prescribed by a qualified oncologist.

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, altering its activity. This triggers degradation of specific transcription factors, leading to anti‑angiogenic, immunomodulatory, and direct anti‑tumor effects that help control malignant cell growth.

The prescribed dose of Lenalidomida Stada is determined individually by the treating physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Patients should follow the exact dosing instructions provided by their healthcare professional.

Lenalidomida Stada is contraindicated in pregnancy because lenalidomide is teratogenic. Women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, and breastfeeding is generally not recommended while receiving the drug.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lenalidomida Stada (lenalidomide) belongs to the immunomodulatory imide drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often combined with dexamethasone or other agents to improve response rates, whereas alternative classes target proteasome activity or surface antigens.

Store Lenalidomida Stada at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat, and direct sunlight to maintain stability and potency.

Lenalidomida Stada is taken orally, usually as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule, including any dose interruptions, is determined by the treating physician based on therapeutic response and tolerability.

Serious risks include venous thromboembolism, severe neutropenia or thrombocytopenia, secondary primary malignancies, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, clotting, or unusual skin changes.

Lenalidomida Stada should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, and patients with uncontrolled severe infections or certain uncontrolled cardiac conditions unless specifically advised by a specialist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lenalidomide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT